Physician
Advanced Pain Care Clinic PSC
Advanced Pain Care Clinic PSC was paid $1.18M by Medicaid between Jan 2018 and May 2019, across 36 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 21% of everything it billed.
33Billing provider infoADVANCED PAIN CARE CLINIC PSC
EVANSVILLE, IN 47714
EVANSVILLE, IN 47714
33aNPI1942378112assigned 12/04/2006
33bProvider typeInterventional Pain Medicine Physician
28Total paid$1.18M
24GClaims40,296
24DCodes billed36
24AFirst – last monthJan 2018 – May 2019
Compared with peers
Next to other Interventional Pain Medicine Physician providers in Indiana
Rank by total paid#1 of 17
Median peer was paid$3K
This provider vs. median374×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 36,472 | $997K | |
| 2019 | 3,824 | $185K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 21% | 14,309 | 12,377 | $251K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 18% | 2,174 | 2,030 | $207K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 17% | 7,445 | 6,627 | $201K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 17% | 6,653 | 6,237 | $201K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 8.1% | 3,509 | 3,280 | $95K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 4.8% | 956 | 860 | $56K |
| 64493 | 2.7% | 437 | 363 | $32K | |
| 76881 | 2.1% | 478 | 406 | $25K | |
| 95911 | 1.7% | 284 | 239 | $20K | |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.5% | 350 | 320 | $17K |
| 64494 | 1.4% | 438 | 362 | $17K | |
| 95886 | 1.3% | 319 | 270 | $15K |
24 more codes
| 64495 | 1.1% | 298 | $13K | |
| 62370 | <1% | 422 | $8K | |
| 64635 | <1% | 21 | $6K | |
| 64636 | <1% | 43 | $5K | |
| 20611 | <1% | 223 | $4K | |
| 76942 | <1% | 129 | $2K | |
| 95923 | <1% | 111 | $1K | |
| 99406 | <1% | 681 | $997.47 | |
| 27096 | <1% | 13 | $945.73 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 58 | $858.82 |
| 93923 | <1% | 169 | $787.09 | |
| 20610 | <1% | 25 | $692.64 | |
| 99407 | <1% | 69 | $521.94 | |
| 62323 | <1% | 12 | $238.30 | |
| 95924 | <1% | 65 | $208.66 | |
| 20552 | <1% | 22 | $204.39 | |
| 95921 | <1% | 87 | $75.58 | |
| 93040 | <1% | 85 | $48.75 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 13 | $26.42 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 15 | $2.48 |
| 90834 | Psychotherapy session, about 45 minutes | 0% | 265 | $0.00 |
| J3490 | Unclassified drugs | 0% | 71 | $0.00 |
| A4220 | Refill kit for implantable infusion pump | 0% | 15 | $0.00 |
| G0659 | Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes | 0% | 32 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSANAPATI, MAHENDRA (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Pain Management Centers of America, PSC | Evansville, IN | $11.24M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.